Categories: NewsPharmaceutical

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024

Northvale, New Jersey–(Newsfile Corp. – November 7, 2024) – Elite Pharmaceuticals, Inc. (OTCQB: ELTP) (“Elite” or the “Company”), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite’s management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company’s financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.

Date: November 15, 2024
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
General questions by 5:00 PM EST on Wednesday, November 13, 2024
Financial questions by 7:00 PM EST on Thursday, November 14, 2024
Audio Replay: https://elite.irpass.com/events_presentations

 

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229053

Staff

Recent Posts

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent…

17 minutes ago

Smartee Unveils ‘Live Update’ to Slash Treatment Planning Time from Days to Seconds

SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive…

2 hours ago

Enhancing Mobility and Independence: VARON Oxygen Concentrators Deliver a New Standard of Freedom and Care

NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and…

2 hours ago

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

CAMBRIDGE, Mass., June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in…

8 hours ago

Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®

Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0…

14 hours ago

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select…

23 hours ago